The world’s first drug that is both an immunomodulator in the tumor microenvironment and cytoprotector in the GI (reducing inflammation and speeding up damaged tissue recovery) with multiple indications.

Promising clinical data from over 260 patients, across 9 clinical trials, suggests that lead candidate, YIV-906, could improve patient outcomes by prolonging survival and elevating quality of life.